Amanote Research
Register
Sign In
High TMB Predicts Immunotherapy Benefit in NSCLC
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-nb2018-048
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
April 16, 2018
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
P3.01-03 the Cost Benefit From Second Line Immunotherapy in Metastatic NSCLC: ASCO Value Framework Prospective
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Tumor Mutational Burden (TMB) Standardization Initiatives: Recommendations for Consistent TMB Assessment in Clinical Samples to Guide Immunotherapy Treatment Decisions
Genes Chromosomes and Cancer
Cancer Research
Genetics
Microsatellite-Stable Tumors With High Mutational Burden Benefit From Immunotherapy
Cancer immunology research
Cancer Research
Immunology
P3.04-14 TMB and Immune Checkpoint Inhibitor Gene Expression Are Unrelated in NSCLC Patients
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
OA11 First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (≥10 Mut/Mb): Results From CheckMate 227
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.16-12 Identification of a Biomarker Panel in Resected NSCLC That Predicts Patient Outcomes and Benefit From Adjuvant Chemotherapy
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
MA19.09 Concurrent Mutations in STK11 and KEAP1 Is Associated With Resistance to PD-(L)1 Blockade in Patients With NSCLC Despite High TMB
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Immunotherapy in SCLC: Exceptional Clinical Benefit and Abscopal Pneumonitis After Radiotherapy
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Radio-Immunotherapy: A Promising Weapon to Consider in the Fight Against NSCLC
International Journal of Radiology & Radiation Therapy
